ZA200505357B - Substituted aniline derivatives - Google Patents
Substituted aniline derivatives Download PDFInfo
- Publication number
- ZA200505357B ZA200505357B ZA200505357A ZA200505357A ZA200505357B ZA 200505357 B ZA200505357 B ZA 200505357B ZA 200505357 A ZA200505357 A ZA 200505357A ZA 200505357 A ZA200505357 A ZA 200505357A ZA 200505357 B ZA200505357 B ZA 200505357B
- Authority
- ZA
- South Africa
- Prior art keywords
- methyl
- alk
- phenyl
- cycloalk
- ethyl ester
- Prior art date
Links
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 226
- -1 {2-Amino-4-[ (3-trifluoromethylphenylamino)methyl]phenyl}carbamic acid Chemical compound 0.000 claims description 52
- 150000003839 salts Chemical class 0.000 claims description 43
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- 206010010904 Convulsion Diseases 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 208000019901 Anxiety disease Diseases 0.000 claims description 22
- 125000002252 acyl group Chemical group 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 21
- 108020001213 potassium channel Proteins 0.000 claims description 20
- 102000004257 Potassium Channel Human genes 0.000 claims description 19
- 206010015037 epilepsy Diseases 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 208000004296 neuralgia Diseases 0.000 claims description 14
- 208000021722 neuropathic pain Diseases 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 230000005764 inhibitory process Effects 0.000 claims description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 230000001537 neural effect Effects 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 208000019695 Migraine disease Diseases 0.000 claims description 8
- 230000036506 anxiety Effects 0.000 claims description 8
- 206010027599 migraine Diseases 0.000 claims description 8
- 206010001497 Agitation Diseases 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 208000014644 Brain disease Diseases 0.000 claims description 6
- 208000032274 Encephalopathy Diseases 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 208000027520 Somatoform disease Diseases 0.000 claims description 5
- 150000001448 anilines Chemical class 0.000 claims description 5
- QHGZFCAIXRVHID-UHFFFAOYSA-N ethyl n-methyl-n-phenylcarbamate Chemical compound CCOC(=O)N(C)C1=CC=CC=C1 QHGZFCAIXRVHID-UHFFFAOYSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 208000027753 pain disease Diseases 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 208000008811 Agoraphobia Diseases 0.000 claims description 4
- 241000589968 Borrelia Species 0.000 claims description 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 208000016604 Lyme disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 206010034912 Phobia Diseases 0.000 claims description 4
- 241000710799 Rubella virus Species 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 230000036461 convulsion Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 230000035987 intoxication Effects 0.000 claims description 4
- 231100000566 intoxication Toxicity 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 201000001716 specific phobia Diseases 0.000 claims description 4
- 125000003944 tolyl group Chemical group 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000004454 Hyperalgesia Diseases 0.000 claims description 3
- 201000001916 Hypochondriasis Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 208000004983 Phantom Limb Diseases 0.000 claims description 3
- 206010056238 Phantom pain Diseases 0.000 claims description 3
- 208000000810 Separation Anxiety Diseases 0.000 claims description 3
- 206010041250 Social phobia Diseases 0.000 claims description 3
- 208000012826 adjustment disease Diseases 0.000 claims description 3
- 206010053552 allodynia Diseases 0.000 claims description 3
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- PAUMPFSSOXRDEJ-UHFFFAOYSA-N ethyl n-[2-amino-4-(anilinomethyl)phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC=C1 PAUMPFSSOXRDEJ-UHFFFAOYSA-N 0.000 claims description 3
- XVKFYUITXXYYEN-UHFFFAOYSA-N ethyl n-[2-amino-4-[(2,4-difluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(F)C=C1F XVKFYUITXXYYEN-UHFFFAOYSA-N 0.000 claims description 3
- VDDRKSVFMCGVKS-UHFFFAOYSA-N ethyl n-[2-amino-4-[(2-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC=C1F VDDRKSVFMCGVKS-UHFFFAOYSA-N 0.000 claims description 3
- RAVCWWJMYAMNLK-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(F)=C1 RAVCWWJMYAMNLK-UHFFFAOYSA-N 0.000 claims description 3
- PZWXBOANAHDGDV-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-butylanilino)methyl]phenyl]carbamate Chemical compound C1=CC(CCCC)=CC=C1NCC1=CC=C(NC(=O)OCC)C(N)=C1 PZWXBOANAHDGDV-UHFFFAOYSA-N 0.000 claims description 3
- DWSPCTCHYKCYFR-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-chloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C=C1 DWSPCTCHYKCYFR-UHFFFAOYSA-N 0.000 claims description 3
- LLYSQBCINNSNKO-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-cyclohexylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C2CCCCC2)C=C1 LLYSQBCINNSNKO-UHFFFAOYSA-N 0.000 claims description 3
- NQNXMCDBIPXRFF-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(F)C=C1 NQNXMCDBIPXRFF-UHFFFAOYSA-N 0.000 claims description 3
- BSCJHOFVPMMXGC-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-methoxyanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(OC)C=C1 BSCJHOFVPMMXGC-UHFFFAOYSA-N 0.000 claims description 3
- NVOFZLPWTFWFDQ-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-phenylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C=2C=CC=CC=2)C=C1 NVOFZLPWTFWFDQ-UHFFFAOYSA-N 0.000 claims description 3
- OVMRYCWHBHWHDB-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-propan-2-ylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(C)C)C=C1 OVMRYCWHBHWHDB-UHFFFAOYSA-N 0.000 claims description 3
- YGDMFPQYDCZIMM-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-tert-butylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(C)(C)C)C=C1 YGDMFPQYDCZIMM-UHFFFAOYSA-N 0.000 claims description 3
- CBUCMNUGRUKIBK-UHFFFAOYSA-N ethyl n-[2-amino-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 CBUCMNUGRUKIBK-UHFFFAOYSA-N 0.000 claims description 3
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 3
- 230000000917 hyperalgesic effect Effects 0.000 claims description 3
- 230000002981 neuropathic effect Effects 0.000 claims description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 208000025874 separation anxiety disease Diseases 0.000 claims description 3
- 208000005809 status epilepticus Diseases 0.000 claims description 3
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 2
- 208000026345 acute stress disease Diseases 0.000 claims description 2
- XFNGDUVFJSECBN-UHFFFAOYSA-N ethyl n-[2-amino-4-[(2,3-dichloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(Cl)=C1Cl XFNGDUVFJSECBN-UHFFFAOYSA-N 0.000 claims description 2
- NPFOVUKAFGUSQL-UHFFFAOYSA-N ethyl n-[2-amino-4-[(2,3-dihydro-1h-inden-5-ylamino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(CCC2)C2=C1 NPFOVUKAFGUSQL-UHFFFAOYSA-N 0.000 claims description 2
- MPNLUKUAXMXGGU-UHFFFAOYSA-N ethyl n-[2-amino-4-[(2,4-dichloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C=C1Cl MPNLUKUAXMXGGU-UHFFFAOYSA-N 0.000 claims description 2
- PJFKUBNCMZLCEL-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3,4-difluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(F)C(F)=C1 PJFKUBNCMZLCEL-UHFFFAOYSA-N 0.000 claims description 2
- STCYUEYAARANPB-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3-chloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(Cl)=C1 STCYUEYAARANPB-UHFFFAOYSA-N 0.000 claims description 2
- RNFBDOBYXLGUBY-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3-methylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(C)=C1 RNFBDOBYXLGUBY-UHFFFAOYSA-N 0.000 claims description 2
- CIYWTQMAZIEXNG-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-methylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C)C=C1 CIYWTQMAZIEXNG-UHFFFAOYSA-N 0.000 claims description 2
- IMAVPOSIWIUFQB-UHFFFAOYSA-N ethyl n-[2-amino-4-[(naphthalen-2-ylamino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C=CC=C2)C2=C1 IMAVPOSIWIUFQB-UHFFFAOYSA-N 0.000 claims description 2
- SHWHGZSYKAZUIB-UHFFFAOYSA-N ethyl n-[2-amino-4-[1-(4-chloroanilino)ethyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1C(C)NC1=CC=C(Cl)C=C1 SHWHGZSYKAZUIB-UHFFFAOYSA-N 0.000 claims description 2
- HIDMNWJFCJAMQI-UHFFFAOYSA-N ethyl n-[2-chloro-4-[(3-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(F)=C1 HIDMNWJFCJAMQI-UHFFFAOYSA-N 0.000 claims description 2
- URAKWDASUSFXKH-UHFFFAOYSA-N ethyl n-[2-chloro-4-[(4-chloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C=C1 URAKWDASUSFXKH-UHFFFAOYSA-N 0.000 claims description 2
- XPAYAFCWAGCEME-UHFFFAOYSA-N ethyl n-[2-chloro-4-[(4-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1CNC1=CC=C(F)C=C1 XPAYAFCWAGCEME-UHFFFAOYSA-N 0.000 claims description 2
- YETJUQCNPAAANG-UHFFFAOYSA-N ethyl n-[2-methyl-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 YETJUQCNPAAANG-UHFFFAOYSA-N 0.000 claims description 2
- PSRTZGHRXNJOEO-UHFFFAOYSA-N ethyl n-[4-[(3,4-difluoroanilino)methyl]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1CNC1=CC=C(F)C(F)=C1 PSRTZGHRXNJOEO-UHFFFAOYSA-N 0.000 claims description 2
- YFYLMPIYVCSHPH-UHFFFAOYSA-N ethyl n-[4-[(3-fluoroanilino)methyl]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(F)=C1 YFYLMPIYVCSHPH-UHFFFAOYSA-N 0.000 claims description 2
- RUVLMXALVIBXME-UHFFFAOYSA-N ethyl n-[4-[(4-chloroanilino)methyl]-2-fluorophenyl]carbamate Chemical compound C1=C(F)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C=C1 RUVLMXALVIBXME-UHFFFAOYSA-N 0.000 claims description 2
- DPIDNSCETUXASM-UHFFFAOYSA-N ethyl n-[4-[(4-chloroanilino)methyl]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C=C1 DPIDNSCETUXASM-UHFFFAOYSA-N 0.000 claims description 2
- JRMWXXMVCOHXCB-UHFFFAOYSA-N ethyl n-[4-[(4-chloroanilino)methyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C=C1 JRMWXXMVCOHXCB-UHFFFAOYSA-N 0.000 claims description 2
- HCLUFHIOGAXFCC-UHFFFAOYSA-N ethyl n-[4-[(4-fluoroanilino)methyl]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1CNC1=CC=C(F)C=C1 HCLUFHIOGAXFCC-UHFFFAOYSA-N 0.000 claims description 2
- UNHRXQWFNONDJR-UHFFFAOYSA-N ethyl n-[4-[1-(4-chloroanilino)ethyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1C(C)NC1=CC=C(Cl)C=C1 UNHRXQWFNONDJR-UHFFFAOYSA-N 0.000 claims description 2
- GCFCPEZENZTFAY-UHFFFAOYSA-N ethyl n-[4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 GCFCPEZENZTFAY-UHFFFAOYSA-N 0.000 claims description 2
- SHXIJKYXFWJGDT-UHFFFAOYSA-N n-[2-chloro-4-[(4-chloroanilino)methyl]phenyl]butanamide Chemical compound C1=C(Cl)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C=C1 SHXIJKYXFWJGDT-UHFFFAOYSA-N 0.000 claims description 2
- SIONWVZOLMLQGG-UHFFFAOYSA-N n-[2-chloro-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]butanamide Chemical compound C1=C(Cl)C(NC(=O)CCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 SIONWVZOLMLQGG-UHFFFAOYSA-N 0.000 claims description 2
- QOUWPCGZCSHNRK-UHFFFAOYSA-N n-[4-[(4-amino-2-methylanilino)methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C(N)C=C1C QOUWPCGZCSHNRK-UHFFFAOYSA-N 0.000 claims description 2
- ANCSKQQFJNCGFC-UHFFFAOYSA-N n-[4-[(4-chloro-3-fluoroanilino)methyl]-2-fluorophenyl]butanamide Chemical compound C1=C(F)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(F)=C1 ANCSKQQFJNCGFC-UHFFFAOYSA-N 0.000 claims description 2
- XFZWRYINWCHARH-UHFFFAOYSA-N n-[4-[(4-chloroanilino)methyl]-2-methylphenyl]butanamide Chemical compound C1=C(C)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C=C1 XFZWRYINWCHARH-UHFFFAOYSA-N 0.000 claims description 2
- SESQTSCDOREBKJ-UHFFFAOYSA-N n-[4-[(4-chloroanilino)methyl]phenyl]butanamide Chemical compound C1=CC(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C=C1 SESQTSCDOREBKJ-UHFFFAOYSA-N 0.000 claims description 2
- PFUWYMNNTQXYIU-UHFFFAOYSA-N n-[4-[[2-(imidazol-1-ylmethyl)anilino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=CC=C1CN1C=NC=C1 PFUWYMNNTQXYIU-UHFFFAOYSA-N 0.000 claims description 2
- AQIYYEYDCKZSCQ-UHFFFAOYSA-N n-[4-[[(2,4-diaminoquinazolin-6-yl)amino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C(N=C(N)N=C2N)C2=C1 AQIYYEYDCKZSCQ-UHFFFAOYSA-N 0.000 claims 2
- VAUTZIXBXVUZQA-UHFFFAOYSA-N 2-[(4-acetamidophenyl)methylamino]-5-chloro-n-(5-chloropyridin-2-yl)benzamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C(Cl)C=C1C(=O)NC1=CC=C(Cl)C=N1 VAUTZIXBXVUZQA-UHFFFAOYSA-N 0.000 claims 1
- LVDKVOBNMQQEAL-UHFFFAOYSA-N ethyl n-[2-(4-chlorophenyl)-4-[(3-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(C=2C=CC(Cl)=CC=2)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(F)=C1 LVDKVOBNMQQEAL-UHFFFAOYSA-N 0.000 claims 1
- JBASQAITBFAGGZ-UHFFFAOYSA-N ethyl n-[2-(4-chlorophenyl)-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(C=2C=CC(Cl)=CC=2)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 JBASQAITBFAGGZ-UHFFFAOYSA-N 0.000 claims 1
- AVLRKXVHQCYJLZ-UHFFFAOYSA-N ethyl n-[2-[4-(dimethylamino)phenyl]-4-[(3-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(C=2C=CC(=CC=2)N(C)C)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(F)=C1 AVLRKXVHQCYJLZ-UHFFFAOYSA-N 0.000 claims 1
- YCMRKXZMNUMKST-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3,4-dichloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C(Cl)=C1 YCMRKXZMNUMKST-UHFFFAOYSA-N 0.000 claims 1
- HFTMLRRJCMKHCO-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3,5-dichloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC(Cl)=CC(Cl)=C1 HFTMLRRJCMKHCO-UHFFFAOYSA-N 0.000 claims 1
- UACNDMSYYWUJNP-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-chloro-3-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C(F)=C1 UACNDMSYYWUJNP-UHFFFAOYSA-N 0.000 claims 1
- BYARLUNDODGUSF-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-cyanoanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C#N)C=C1 BYARLUNDODGUSF-UHFFFAOYSA-N 0.000 claims 1
- VRXUASWAYZPEHF-UHFFFAOYSA-N ethyl n-[2-amino-4-[1-[4-(trifluoromethyl)anilino]ethyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1C(C)NC1=CC=C(C(F)(F)F)C=C1 VRXUASWAYZPEHF-UHFFFAOYSA-N 0.000 claims 1
- PYVCGNWJTVIAMS-UHFFFAOYSA-N ethyl n-[2-amino-4-[[3-fluoro-4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C(F)=C1 PYVCGNWJTVIAMS-UHFFFAOYSA-N 0.000 claims 1
- PJQJLRQLLHQJMP-UHFFFAOYSA-N ethyl n-[2-chloro-4-[(3,4-dichloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C(Cl)=C1 PJQJLRQLLHQJMP-UHFFFAOYSA-N 0.000 claims 1
- YHALLHHMBWALKL-UHFFFAOYSA-N ethyl n-[2-chloro-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 YHALLHHMBWALKL-UHFFFAOYSA-N 0.000 claims 1
- FBWLGGCIJQPAGG-UHFFFAOYSA-N ethyl n-[2-fluoro-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(F)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 FBWLGGCIJQPAGG-UHFFFAOYSA-N 0.000 claims 1
- TZNQYORNTRQEJV-UHFFFAOYSA-N ethyl n-[4-[(4-chloro-3-fluoroanilino)methyl]-2-fluorophenyl]carbamate Chemical compound C1=C(F)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C(F)=C1 TZNQYORNTRQEJV-UHFFFAOYSA-N 0.000 claims 1
- ILXWQQLVKRBUAO-UHFFFAOYSA-N n-[2-amino-4-[(3-fluoroanilino)methyl]phenyl]-2,2-dimethylpropanamide Chemical compound C1=C(N)C(NC(=O)C(C)(C)C)=CC=C1CNC1=CC=CC(F)=C1 ILXWQQLVKRBUAO-UHFFFAOYSA-N 0.000 claims 1
- AOSDPVXNYCUYSW-UHFFFAOYSA-N n-[2-chloro-4-[(3,4-dichloroanilino)methyl]phenyl]butanamide Chemical compound C1=C(Cl)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(Cl)=C1 AOSDPVXNYCUYSW-UHFFFAOYSA-N 0.000 claims 1
- HSXJTDIWKDHOPI-UHFFFAOYSA-N n-[2-chloro-4-[(3-fluoroanilino)methyl]phenyl]butanamide Chemical compound C1=C(Cl)C(NC(=O)CCC)=CC=C1CNC1=CC=CC(F)=C1 HSXJTDIWKDHOPI-UHFFFAOYSA-N 0.000 claims 1
- DBLOEDMPCORMST-UHFFFAOYSA-N n-[2-chloro-4-[(4-chloro-3-fluoroanilino)methyl]phenyl]butanamide Chemical compound C1=C(Cl)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(F)=C1 DBLOEDMPCORMST-UHFFFAOYSA-N 0.000 claims 1
- HRQLXROTHVOVME-UHFFFAOYSA-N n-[2-chloro-4-[(4-fluoroanilino)methyl]phenyl]butanamide Chemical compound C1=C(Cl)C(NC(=O)CCC)=CC=C1CNC1=CC=C(F)C=C1 HRQLXROTHVOVME-UHFFFAOYSA-N 0.000 claims 1
- VNXLQHITRXDULI-UHFFFAOYSA-N n-[2-fluoro-4-[(3-fluoroanilino)methyl]phenyl]butanamide Chemical compound C1=C(F)C(NC(=O)CCC)=CC=C1CNC1=CC=CC(F)=C1 VNXLQHITRXDULI-UHFFFAOYSA-N 0.000 claims 1
- YIJKAGUJZZPFTO-UHFFFAOYSA-N n-[2-fluoro-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]butanamide Chemical compound C1=C(F)C(NC(=O)CCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 YIJKAGUJZZPFTO-UHFFFAOYSA-N 0.000 claims 1
- NHXHKDUACVRVPF-UHFFFAOYSA-N n-[4-[(3,4-dichloroanilino)methyl]-2-fluorophenyl]butanamide Chemical compound C1=C(F)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(Cl)=C1 NHXHKDUACVRVPF-UHFFFAOYSA-N 0.000 claims 1
- IIHYQCLDAORSCI-UHFFFAOYSA-N n-[4-[(3,4-dichloroanilino)methyl]-2-methylphenyl]butanamide Chemical compound C1=C(C)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(Cl)=C1 IIHYQCLDAORSCI-UHFFFAOYSA-N 0.000 claims 1
- USVPVZBUNHDWDV-UHFFFAOYSA-N n-[4-[(3,4-dichloroanilino)methyl]phenyl]butanamide Chemical compound C1=CC(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(Cl)=C1 USVPVZBUNHDWDV-UHFFFAOYSA-N 0.000 claims 1
- AJURBOPYTAEEME-UHFFFAOYSA-N n-[4-[(3-fluoroanilino)methyl]-2-methylphenyl]butanamide Chemical compound C1=C(C)C(NC(=O)CCC)=CC=C1CNC1=CC=CC(F)=C1 AJURBOPYTAEEME-UHFFFAOYSA-N 0.000 claims 1
- GLIFJWDTFOEGAR-UHFFFAOYSA-N n-[4-[(4-amino-3,5-dichloroanilino)methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC(Cl)=C(N)C(Cl)=C1 GLIFJWDTFOEGAR-UHFFFAOYSA-N 0.000 claims 1
- VOOCWXWSNXHKBV-UHFFFAOYSA-N n-[4-[(4-amino-3-methylanilino)methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C(N)C(C)=C1 VOOCWXWSNXHKBV-UHFFFAOYSA-N 0.000 claims 1
- IUICPWUFTFHFNJ-UHFFFAOYSA-N n-[4-[(4-aminoanilino)methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C(N)C=C1 IUICPWUFTFHFNJ-UHFFFAOYSA-N 0.000 claims 1
- CKRMGYYYPLOCHM-UHFFFAOYSA-N n-[4-[(4-chloro-3-fluoroanilino)methyl]phenyl]butanamide Chemical compound C1=CC(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(F)=C1 CKRMGYYYPLOCHM-UHFFFAOYSA-N 0.000 claims 1
- YNWPLUKYJAPYJQ-UHFFFAOYSA-N n-[4-[(4-chloroanilino)methyl]-2-fluorophenyl]butanamide Chemical compound C1=C(F)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C=C1 YNWPLUKYJAPYJQ-UHFFFAOYSA-N 0.000 claims 1
- IMMNNWSVPCTHKC-UHFFFAOYSA-N n-[4-[(4-fluoroanilino)methyl]-2-methylphenyl]butanamide Chemical compound C1=C(C)C(NC(=O)CCC)=CC=C1CNC1=CC=C(F)C=C1 IMMNNWSVPCTHKC-UHFFFAOYSA-N 0.000 claims 1
- BDFMGMYOZMUMDN-UHFFFAOYSA-N n-[4-[[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)amino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C2C(C)(C)CCC(C)(C)C2=C1 BDFMGMYOZMUMDN-UHFFFAOYSA-N 0.000 claims 1
- YXWRKVOHJVXRFZ-UHFFFAOYSA-N n-[4-[[3-(imidazol-1-ylmethyl)anilino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=CC(CN2C=NC=C2)=C1 YXWRKVOHJVXRFZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 17
- 108091006146 Channels Proteins 0.000 description 15
- 229960003312 retigabine Drugs 0.000 description 15
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 150000002431 hydrogen Chemical class 0.000 description 9
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000001773 anti-convulsant effect Effects 0.000 description 8
- 125000004494 ethyl ester group Chemical group 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 239000001961 anticonvulsive agent Substances 0.000 description 7
- 229960003965 antiepileptics Drugs 0.000 description 7
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 230000002082 anti-convulsion Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 125000001624 naphthyl group Chemical group 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 108010038888 KCNQ3 Potassium Channel Proteins 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010011878 Deafness Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 210000004727 amygdala Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 231100000895 deafness Toxicity 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 208000016354 hearing loss disease Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000001535 kindling effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 102100034360 Potassium voltage-gated channel subfamily KQT member 3 Human genes 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000008409 Romano-Ward Syndrome Diseases 0.000 description 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000002059 anti-epileptogenic effect Effects 0.000 description 2
- 230000001977 ataxic effect Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 201000006908 long QT syndrome 1 Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000008587 neuronal excitability Effects 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 229960001416 pilocarpine Drugs 0.000 description 2
- 230000007824 polyneuropathy Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 208000008882 Benign Neonatal Epilepsy Diseases 0.000 description 1
- 206010067866 Benign familial neonatal convulsions Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000002877 Epileptic Syndromes Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000974726 Homo sapiens Potassium voltage-gated channel subfamily E member 1 Proteins 0.000 description 1
- 101000994648 Homo sapiens Potassium voltage-gated channel subfamily KQT member 4 Proteins 0.000 description 1
- 101000994656 Homo sapiens Potassium voltage-gated channel subfamily KQT member 5 Proteins 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 description 1
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 102100022755 Potassium voltage-gated channel subfamily E member 1 Human genes 0.000 description 1
- 102100034365 Potassium voltage-gated channel subfamily KQT member 5 Human genes 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 230000006400 anxiety behaviour Effects 0.000 description 1
- 230000007529 anxiety like behavior Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical class O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000003452 benign familial neonatal epilepsy Diseases 0.000 description 1
- 201000010295 benign neonatal seizures Diseases 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960004414 clomethiazole Drugs 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000003804 effect on potassium Effects 0.000 description 1
- 230000008918 emotional behaviour Effects 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- SMZPSCLWIVWFLG-UHFFFAOYSA-N ethyl n-(2-phenylphenyl)carbamate Chemical compound CCOC(=O)NC1=CC=CC=C1C1=CC=CC=C1 SMZPSCLWIVWFLG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000011686 genetic mapping animal model Methods 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- JTNKTTCJVFXBEH-UHFFFAOYSA-N n-[4-[(3,4,5-trimethoxyanilino)methyl]phenyl]acetamide Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C=CC(NC(C)=O)=CC=2)=C1 JTNKTTCJVFXBEH-UHFFFAOYSA-N 0.000 description 1
- FCNULWHUEPGFAA-UHFFFAOYSA-N n-[4-[[4-(imidazol-1-ylmethyl)anilino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC(C=C1)=CC=C1CN1C=NC=C1 FCNULWHUEPGFAA-UHFFFAOYSA-N 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000008555 neuronal activation Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960005152 pentetrazol Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- 230000018448 secretion by cell Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000031893 sensory processing Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 description 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 1
- 229960001918 tiagabine Drugs 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- 210000000836 trigeminal nuclei Anatomy 0.000 description 1
- 210000004496 type 1 vestibular hair cell Anatomy 0.000 description 1
- 210000001213 vestibule labyrinth Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200300392 | 2003-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200505357B true ZA200505357B (en) | 2006-12-27 |
Family
ID=58707220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200505357A ZA200505357B (en) | 2003-03-14 | 2004-03-12 | Substituted aniline derivatives |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060167087A1 (zh) |
| KR (1) | KR20050117563A (zh) |
| CN (1) | CN1759099A (zh) |
| AR (1) | AR043507A1 (zh) |
| CL (1) | CL2004000488A1 (zh) |
| EA (1) | EA200501299A1 (zh) |
| IS (1) | IS7924A (zh) |
| NO (1) | NO20054721L (zh) |
| NZ (1) | NZ541242A (zh) |
| SG (1) | SG171472A1 (zh) |
| UA (1) | UA81799C2 (zh) |
| ZA (1) | ZA200505357B (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7799832B2 (en) * | 2003-10-23 | 2010-09-21 | Valeant Pharmaceuticals North America | Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| US8722929B2 (en) * | 2006-10-10 | 2014-05-13 | Valeant Pharmaceuticals International | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators |
| US8563566B2 (en) * | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| US7786146B2 (en) * | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
| JP2011525538A (ja) * | 2008-06-24 | 2011-09-22 | バレアント プハルマセウトイカルス インターナショナル | カリウムチャネルモジュレーターとして有用なベンジルオキシアニリド誘導体 |
| US20130210883A1 (en) | 2010-05-21 | 2013-08-15 | Johannes Grillari | Lipase inhibitors |
| EP2571988B1 (en) | 2010-05-21 | 2019-11-20 | Universität für Bodenkultur Wien | Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders |
| EP3263559A1 (en) * | 2013-01-22 | 2018-01-03 | Technische Universität Graz | Lipase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3903989A1 (de) * | 1989-02-10 | 1990-09-20 | Basf Ag | Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika |
| EP0515684A4 (en) * | 1990-02-14 | 1993-04-21 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor of denatured ldl formation |
| US6472165B1 (en) * | 1999-08-03 | 2002-10-29 | Arzneimittelwerk Dresden Gmbh | Modulatory binding site in potassium channels for screening and finding new active ingredients |
| EP1369420A1 (en) * | 2002-06-06 | 2003-12-10 | Aventis Pharma Deutschland GmbH | Inhibitors of the GPib - vWF interaction |
-
2004
- 2004-03-08 AR ARP040100733A patent/AR043507A1/es not_active Application Discontinuation
- 2004-03-10 CL CL200400488A patent/CL2004000488A1/es unknown
- 2004-03-12 SG SG200718941-8A patent/SG171472A1/en unknown
- 2004-03-12 CN CNA2004800067754A patent/CN1759099A/zh active Pending
- 2004-03-12 EA EA200501299A patent/EA200501299A1/ru unknown
- 2004-03-12 KR KR1020057017223A patent/KR20050117563A/ko not_active Application Discontinuation
- 2004-03-12 US US10/549,345 patent/US20060167087A1/en not_active Abandoned
- 2004-03-12 ZA ZA200505357A patent/ZA200505357B/en unknown
- 2004-03-12 NZ NZ541242A patent/NZ541242A/en unknown
- 2004-12-03 UA UAA200508717A patent/UA81799C2/uk unknown
-
2005
- 2005-06-30 IS IS7924A patent/IS7924A/is unknown
- 2005-10-13 NO NO20054721A patent/NO20054721L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SG171472A1 (en) | 2011-06-29 |
| KR20050117563A (ko) | 2005-12-14 |
| UA81799C2 (uk) | 2008-02-11 |
| US20060167087A1 (en) | 2006-07-27 |
| NZ541242A (en) | 2009-01-31 |
| IS7924A (is) | 2005-06-30 |
| AR043507A1 (es) | 2005-08-03 |
| CN1759099A (zh) | 2006-04-12 |
| CL2004000488A1 (es) | 2005-01-07 |
| EA200501299A1 (ru) | 2006-02-24 |
| NO20054721L (no) | 2005-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200504528B (en) | Gaming machine | |
| US10597381B2 (en) | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | |
| CA2167524C (en) | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders | |
| AU2004222626B2 (en) | Substituted p-diaminobenzene derivatives | |
| AU2017254522A1 (en) | Compounds and compositions for treating conditions associated with NLRP activity | |
| NO20041112L (no) | 1-Substituerte-1-aminometyl-cykloalkanderivater (=gabapentinanaloger), deres fremstilling og deres anvendelse ved behandiing av neurologiske lidelser | |
| US6313174B1 (en) | Aminobenzophenones as inhibitors of interleukin and TNF | |
| NO20061550L (no) | Kombinasjon som innbefatter en alfa-2-delta ligand og en SSRO og/eller SNRI for behandling av depresjon og angstforstyrrelser | |
| US6323240B1 (en) | 4-phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity | |
| HU211550A9 (en) | N-phenylalkyl substituted alfa-amino carboxamide derivatives and process for their preparation | |
| BRPI0413533A (pt) | derivados de malonamida que bloqueiam a atividade de gama-secretase | |
| WO2009008905A1 (en) | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning | |
| ZA200505357B (en) | Substituted aniline derivatives | |
| AU2003287922A1 (en) | 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system | |
| AU2004220424B2 (en) | Substituted aniline derivatives | |
| Zhao et al. | Curcumin protects rabbit articular chondrocytes against sodium nitroprusside-induced apoptosis in vitro | |
| AU768473B2 (en) | Novel aminobenzophenones | |
| CN101282940A (zh) | 含氟化合物 | |
| ZA200507183B (en) | Substituted P-diaminobenzene derivatives | |
| JP2003523993A5 (zh) | ||
| CA3210962A1 (en) | Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures | |
| ZA200507186B (en) | Substituted indoline and indole derivatives | |
| NZ549725A (en) | Combination of agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing it | |
| KR20030058934A (ko) | 중추신경계의 급성 및 만성적 손상에 기인한 신경세포의퇴화를 방지하기 위한 화합물, 조성물 및 방법 | |
| US20080033045A1 (en) | Treatment of psychiatric disorders |